Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clin... ( CALGARY Oct. 24 / Oncolytics Biot...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial

Date:10/23/2007

CALGARY, Oct. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that a poster presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN(R)/radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The conference runs from October 22-26, 2007.

"We are very encouraged with the results of this trial to date," said Dr. Brad Thompson, President and CEO of Oncolytics. "The data is supportive of our ongoing Phase II REOLYSIN(R)/radiation cotherapy trial in the U.K."

The interim results of the Ia/Ib trial demonstrate that intratumoural treatment with REOLYSIN(R) and radiation is well tolerated and results in both local and remote anti-tumour activity in patients with a variety of advanced cancers. Oncolytics continues to enroll patients in the Ib portion of this trial, and is also actively enrolling patients in a Phase II trial examining this treatment combination.

The presentation, entitled "A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN(R)) in combination with radiation in patients with advanced malignancies" will be delivered by Dr. Dean Harris of The Institute of Cancer Research, London.

These interim results were also presented in early October at the National Cancer Research Institute (NCRI) Cancer Conference in Birmingham, U.K.

The poster presentation will be posted on the Oncolytics website today at http://www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion

Post Your Comments:

(Date:6/18/2013)... 18, 2013 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its preliminary unaudited financial results for the fourth ... March 31, 2013. Fourth Quarter of ... quarter of fiscal 2013 increased by 33.3% to RMB133.0 ...

(Date:6/18/2013)... (PRWEB) June 18, 2013 In support ... sustainability, the Consulate General of Switzerland in New York ... Switzerland’s MS Tûranor PlanetSolar , to Manhattan. ... its DeepWater Expedition 2013 tour with scientists on board ... Capitain Gérard d’Aboville, runs exclusively on energy from the ...

(Date:6/18/2013)... 18, 2013 (PRWEB) June 18, 2013 ... attendance system in North America, has introduced AccountLinx ... data and payroll records between ExakTime’s software and ... automates ExakTime software setup and keeps employee databases ... data from a business’ current payroll software, directly ...

(Date:6/18/2013)... (PRWEB) June 18, 2013 The ... opening of two new offices in Asia—one in Singapore ... will serve as RAPS’ Pan-Asia office , serving ... be more focused on audiences within China. , The ... its partnership with five Singapore government agencies to develop ...

[0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City [0] ExakTime Introduces AccountLinx Plus [0] RAPS Opens Offices in Singapore and China

... Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ... appointment of Bruce A.,Peacock to the NeurogesX board ... a venture partner with SV Life Sciences, LLC. ... Peacock held senior executive,positions with a number of ...

... 5 Hyperion,Therapeutics, a biopharmaceutical company focused on ... for the,treatment of Urea Cycle Disorders (UCD) and ... B financing. Leading the round was,Sofinnova Ventures, with ... of Menlo Park, CA. WRF Capital of Seattle, ...

... - World,s First Closed-Chest Procedures with Cardica,s C-Port Flex A ... ... REDWOOD CITY, Calif., Sept. 5 Cardica, Inc.,(Nasdaq: CRDC ... performed ground-breaking minimally-invasive,closed-chest bypass procedures using Cardica,s C-Port Flex A ...

Cached Biology Technology:NeurogesX Appoints New Director to the Board 2 NeurogesX Appoints New Director to the Board 3 Hyperion Therapeutics Secures $40 Million In Series B Round 2 Cardica's C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries 2 Cardica's C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries 3 Cardica's C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries 4

NeurogesX Appoints New Director to the Board Hyperion Therapeutics Secures $40 Million In Series B Round Cardica's C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries

(Date:6/18/2013)... Researchers from the United Kingdom, the Energy Department,s ... of Kentucky have recently published a paper describing ... borer Limnoria quadripunctata , commonly known as ... because they exhibit a relatively unique ability to ... microbes to break down the biomass they eat. ...

(Date:6/18/2013)... been awarded a $394,300 grant from the Tarrant ... flow in the new facilities of the 150-mile ... associate professor of civil engineering, will investigate the ... the water in an effort to eliminate biological ... Adding monochloramine is widely practiced throughout the United ...

(Date:6/18/2013)... At Brandeis University, sophisticated computational models and advances ... the complex interplay between genomic data, virus structure ... critical for replication. , "We ... will help researchers alter virus assembly, leaving viruses ... first author of the scientific paper describing the ...

Breaking Biology News(10 mins):Novel enzyme from tiny gribble could prove a boon for biofuels research 2 UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2 Computer modeling technique goes viral at Brandeis 2

[0] Novel enzyme from tiny gribble could prove a boon for biofuels research [0] UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline [0] Computer modeling technique goes viral at Brandeis

... Jan. 8 Pixelplus Co.,Ltd. (Nasdaq: ... Korea that designs,develops, and markets CMOS image ... that it unveiled the "PM1002", the Company,s,new ... The PM1002 integrates a 32-bit RISC ...

... have developed a new nanobiotechnology that enables magnetic ... describe the technology, which could lead to finely-tuned ... issue of Nature Nanotechnology (published online January 3). ... PhD, of Childrens program in Vascular Biology, in ...

... transcription -- the intricate transfer of information from a ... RNA -- isn,t stationed in special "transcription factories" within ... enzyme RNA polymerase II (Pol II) and other key ... gene, regardless of the gene,s position., The findings, published ...

Cached Biology News:Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition 2 Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition 3 An 'attractive' man-machine interface 2 An 'attractive' man-machine interface 3 Research sheds light on the mechanics of gene transcription 2

Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition An 'attractive' man-machine interface Research sheds light on the mechanics of gene transcription

... LNA technology enables sensitive and specific detection ... miRCURY LNA in situ detection probes have ... specific and sensitive detection of miRNAs. Specific ... in whole mounts, thin sections, single cells ...

... kit contains enough separation reagents ... total of 5 x 10 ... the StemSep red magnet and ... buffers for the specific cell ...

... Product Mouse monoclonal [1320] to RFC1 ... p37 subunit of human Replication Factor C expressed ... Cross-reacts with Human and S. cerevisiae. Not yet ... p37 subunit of RFC1 Background Information ...

... a K-12 strain ideally suited as an ... transformation efficiency, blue/white screening capability (with appropriate ... in high yields of excellent quality plasmid ... potentially useful as a stringent host due ...

Biology Products:

miRCURY LNA in situ Detection probes from Exiqon StemSep Hu-Mu Chimera Starter Kit, Kit from StemCell Technologies, Inc.Mouse Anti-RFC1 Monoclonal Antibody, Unconjugated, 1320 from GeneTex NovaBlue Glycerol Stock from Novagen